A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients
HIV Infections

About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Vaccines, Synthetic, AIDS Vaccines, DNA, Viral
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Low doses of nonprescription NSAIDS, acetaminophen, ibuprofen, aspirin, replacement hormone therapy, and vitamin supplements. Patients must have: Asymptomatic HIV infection with no acute related infection. CD4 count >= 500 cells/mm3. Normal hematologic, renal, hepatic, metabolic, and endocrine function. NOTE: No more than one patient over 50 years of age is permitted at each dose level. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Residual toxicity from prior drug treatment. Hypersensitivity to bupivacaine or amide-type local anesthetic. Active viral hepatitis, autoimmune disorders, or other debilitating chronic diseases. Concurrent Medication: Excluded: Medications that affect immune function. Antiretrovirals. Patients with the following prior conditions are excluded: Malignancies other than curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. History of anaphylaxis to vaccines. Prior Medication: Excluded: Prior immunization with any experimental HIV vaccines. Other experimental therapy within 30 days prior to study entry. Prior cancer chemotherapy. Antiretrovirals within 3 months prior to study entry. Prior Treatment: Excluded: Prior radiotherapy. IV drug use or any other high-risk behavior.
Sites / Locations
- Univ of Pennsylvania Med Ctr